FVCM
VRTX icon

F&V Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

F&V Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,645
Closed -$1.65M – 63
2025
Q4 		$1.65M Buy
+3,645
New +$1.57M 0.35% 35

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

F&V Capital Management's VRTX Position: Q1 2026 in Review

F&V Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q1 2026, closing a stake of 3,645 shares — an estimated $1.65M sold.

F&V Capital Management first reported a position in VRTX in Q4 2025 and held it in 1 quarter. The position peaked at $1.65M in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • F&V Capital Management reported no remaining Vertex Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • F&V Capital Management sold 3,645 Vertex Pharmaceuticals shares in Q1 2026, an estimated $1.65M.
  • F&V Capital Management first reported a position in Vertex Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • F&V Capital Management's Vertex Pharmaceuticals position peaked at $1.65M in Q4 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on F&V Capital Management's 13F filing for Q1 2026, filed 27 Apr 2026.